Compare Abeona Therapeutics Inc (ABEO) vs iShares MSCI Hong Kong ETF (EWH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MSCI Hong Kong ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while iShares MSCI Hong Kong ETF trades at $21.14. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | EWH | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $24.55 |
52-Week Low | $4.17 | $19.91 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EWH trades at $21.23, up 1.43% over the past 24 hours, with technical indicators showing a bearish trend from moving averages but neutral oscillators. The stock faces resistance and support clustered around $21, indicating consolidation. Recent corporate actions include a $0.35 dividend scheduled for June 2026. Market sentiment is influenced by Hong Kong's evolving role as a financial hub and regional economic developments.
Outlook remains cautious due to bearish technical signals and limited fundamental data visibility. Investment opportunities hinge on Hong Kong's economic resilience and IPO market growth, while risks include regulatory scrutiny and geopolitical tensions affecting Asian markets. Investors should await clearer financial metrics for a comprehensive assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →
